Physician profile
Robert Decristofano
NPI 1881702165
$957.00
in general payments reported to CMS, 2019-2025
11 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.85 · 2020: $54.43 · 2021: $152 · 2022: $70.80 · 2023: $187 · 2024: $278 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $193.10 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $136.61 | 2021-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $113.95 | 2023-2025 | |
| Glaxosmithkline, LLC. | $105.60 | 2023-2025 | Bexsero, Rotarix, Pediarix |
| Ironshore Pharmaceuticals INC. | $92.42 | 2023-2024 | Jornay Pm |
| Seqirus USA INC | $72.27 | 2024-2025 | Flucelvax |
| Sanofi Pasteur INC. | $72.18 | 2023-2024 | |
| Tris Pharma INC | $56.42 | 2020-2022 | |
| Genentech USA, INC. | $42.77 | 2019-2022 | |
| Alk-Abello, INC | $42.43 | 2025 | Neffy, Grastek, Odactra |
| Supernus Pharmaceuticals, INC. | $29.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Decristofano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.